Introduction
Within the brain there exists an extensive, largely diffuse and often paired network of inhibitory and excitatory neurones. In recent years it has been discovered that neurones can co-release different neurotransmitters, and that the 'excitatory tone' can be modulated on a neurone-by-neurone level (by direct neurotransmitter release at a synapse) or over a region through extra-synaptic receptors.
γ-amino butyric acid (GABA)
The action of γ-amino butyric acid on a GABA A -receptor site within a 5 subunit-based protein in the neuronal membrane causes a conformational change in that protein that allows passage of chloride ions intracellularly, reducing the activity of the neuron by hyperpolarising it. GABA B receptors are Gprotein coupled. GABA C receptors are similar to GABA A , but found in the retina.
About 80% of GABA A -responsive chloride channels consist of αβγ subunits (Figure 1) , although others exist and indeed α, β and γ subunits can be further subdivided (α 1-6 , β 1-3 and γ 1-3 ). In addition to the GABA binding site, other sites exist which allowing binding of other substances that can modify the effect of GABA on the channel.
Barbituric acid
This compound was first synthesised in 1864 and is named after St Barbara, the patron saint of artillery men in whose company the successful chemist celebrated. Many derivatives have been synthesised over the years. Active compounds exert their action through a binding site on α subunits, increasing the length of time the chloride channel is opened in response to GABA, resulting in an enhanced inhibitory effect that leads to sedation, hypnosis, anti-anxiety and anti-epileptic effects. Barbiturates are usually very lipid soluble. Rapid redistribution from the central nervous system (CNS) into fatty compartments after a bolus dose of thiopental accounts for its short initial duration of action, but this gets rapidly longer as the drug is infused, due to sequestration into fatty tissue which then acts as a depot. These drugs are hepatically metabolised, usually to inactive compounds.
Benzodiazepines
These were subsequently synthesised in the search to find equivalent drugs with lower abuse potential than barbiturates. The first (chlordiazepoxide) was made in 1954. Binding to a site between α and γ subunits, benzodiazepines increase the frequency of chloride-channel opening in response to GABA.
Midazolam is perhaps the most frequently employed benzodiazepine in British critical care practice; its short half life is due to rapid metabolism to the active hydroxyl-midazolam glucuronide metabolite that is rapidly renally cleared. Cytochrome P450 3A4 (CYP3A4) is responsible for much of this metabolism, and is found in both the liver and in the gut wall. Its action can be inhibited through co-administration with azole antifungals and macrolides. Accumulation of active metabolite occurs in renal failure; renal replacement therapies will remove a proportion of the metabolite, but not spectacularly so and do not remove the parent compound to any appreciable extent.
Lorazepam has a much longer half-life, but is metabolised to an inactive metabolite by direct glucuronidation.
Other drugs acting on chloride channels include propofol, ethanol and etomidate. These agents seem to target specific subtypes of the chloride channel, and research efforts have tried to discover ligands that have specificity for benzodiazepine binding sites that are made up from specific subunit subtypes. For example α 1 -containing channels appear to be more involved in mediating sedation and so "Z" drugs such as zolpidem have been developed in an attempt to selectively target these channels. Other ligands have been produced (but not marketed) that target α 2 or α 3 subunitcontaining channels in an attempt to achieve anxiolysis without sedation. Gaboxadol targets δ-containing subunits that appear in extra-synaptic chloride channels. Activating these causes marked sedation, increasing slow wave EEG activity with little effect on REM sleep (ie mimicking natural sleep more than other agents).
It is looking increasingly likely that drugs can be developed
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Our understanding of the pharmacology and pharmacokinetics of agents acting on the central nervous system has made considerable advances. This article describes the actions of the drugs most commonly used in critical care units for sedation of critically ill patients. 
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to target specific GABA-mediated chloride channel subtypes and separate the various clinical activities of non-selective benzodiazepines, specifically anxiolysis, sedation and myelorelaxation.
Glutamic acid
The action of glutamate on a protein consisting of a complex of four subunits (Figure 2 ) leads to the formation of an ion channel that allows the passage of cations intracellularly (Ca ++ , Na + , K + ), rendering the resting membrane potential more positive and the membrane more likely to depolarise in response to other neurotransmitters. Thus, glutamate increases the likelihood of a neuron firing. Three main families of glutamate-responsive channels have been discovered so far:
• kainate responsive • α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) responsive • n-methyl-d-aspartate (NMDA) responsive. Only NMDAresponsive channels have so far been successfully targeted for sedative drugs.
Phenylcyclidine (PCP) was the first agent described, patented in 1952. Its side effects are problematic and it was withdrawn in 1965 after the introduction of ketamine, which was specifically developed in an attempt to reduce the hallucinogenic potential. Ketamine is known to also act on opioid receptors, specifically µ and σ receptors, and this explains at least part of ketamine' s additional analgesic effect. Racemic ketamine consists of two chiral isomers; the S-form has been separately marketed as faster acting, with a faster offset and reduced hallucinogenic potential.
Ketamine has a short half-life (2.5-3 hours) and is extensively hepatically cleared. CYP3A4 is implicated again, but there are other routes of metabolism that reduce the potential for drug interactions as a result of CYP3A4 inhibition.
Noradrenaline
Noradrenaline fibres extensively innervate the brain, with vast numbers of neurones projecting from the locus coeruleus (literally "dark blue place") located in the fourth ventricle in the brain stem. Release of noradrenaline from these fibres is excitatory, increasing alertness, cognition, motivation and activation of the hypothalamic-pituitary-adrenal axis. The locus coeruleus is inactive in sleep. The first drug that inactivates this system was discovered by accident in 1962. Boehringer Ingelheim were searching for a new adrenergic agent to be used as a nasal decongestant. Compound ST-155 caused vasoconstriction and was sent for further analysis. The investigating doctor made a solution and administered it to his secretary who had a cold and she quickly became bradycardic, hypotensive and slept for a day afterwards.
Subsequent work showed that ST-155 is 220 times more active at presynaptic α 2 -receptors (G-protein coupled), activation of which causes inhibition of noradrenaline release from the nerve terminal. ST-155 was launched as clonidine in 1966. Even α 2 -receptors have now been subclassified from α 2A to α 2D . It is likely that α 2A mediates sedative and analgesic effects, α 2B mediates cardiovascular effects while α 2C may mediate analgesic effects. The locus coeruleus contains α 2A receptors, but not α 2B or α 2C receptors.
Clonidine has a long half-life of 12-33 hours and although a proportion is cleared by the kidney, the remainder is metabolised by minor pathways that mean metabolic drug interactions are unlikely.
Dexmedetomidine was launched in the United States in 2000. It is more selective for α 2 -receptors than clonidine, possessing 1,620 times more activity at α 2 receptors than α 1 receptors. This confers sedation that mimics natural sleep, with fewer cardiovascular side-effects than clonidine. The half life of dexmedetomidine is two hours. It is cleared by hepatic metabolism via enzyme systems that are unlikely to suffer interactions with other medications.
Conclusion
A wide range of therapeutically useful compounds are active against the systems described above. Research in recent years hints at the future therapeutic potential of these systems for sedation and anxiolysis, and that new compounds to make our patients comfortable in the critical care environment are just around the corner.
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